Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cho-Ming Loi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acidTheunis C Goosen, Jonathan N Bauman, John A Davis, et al.
Pharmacogenomics|April 6, 2016
Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWGWilliam Brian, Larry M Tremaine, Million Arefayene, et al.
International Journal of Hematology|October 22, 2013
Cardiovascular differentiation of imatinib and bosutinib in the ratJonathan R Heyen, Wenyue Hu, Joseph Jamieson, et al.
Chemical Research in Toxicology|January 17, 2009
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolitesDeepak Dalvie, R Scott Obach, Ping Kang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2011
How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potentialEugenia Kraynov, Steven W Martin, Susan Hurst, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthBrion W Murray, Chuangxing Guo, Joseph Piraino, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of painChristopher Deur, Arun K Agrawal, Heidi Baum, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acidTheunis C Goosen, Jonathan N Bauman, John A Davis, et al.
Pharmacogenomics|April 6, 2016
Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWGWilliam Brian, Larry M Tremaine, Million Arefayene, et al.
International Journal of Hematology|October 22, 2013
Cardiovascular differentiation of imatinib and bosutinib in the ratJonathan R Heyen, Wenyue Hu, Joseph Jamieson, et al.
Chemical Research in Toxicology|January 17, 2009
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolitesDeepak Dalvie, R Scott Obach, Ping Kang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2011
How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potentialEugenia Kraynov, Steven W Martin, Susan Hurst, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthBrion W Murray, Chuangxing Guo, Joseph Piraino, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of painChristopher Deur, Arun K Agrawal, Heidi Baum, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 2